Krystal Biotech, Inc.

NasdaqGS:KRYS Stock Report

Market Cap: US$7.5b

Krystal Biotech Management

Management criteria checks 2/4

Krystal Biotech's CEO is Krish Krishnan, appointed in Jan 2016, has a tenure of 10.17 years. total yearly compensation is $15.60M, comprised of 5.1% salary and 94.9% bonuses, including company stock and options. directly owns 5.36% of the company’s shares, worth $399.85M. The average tenure of the management team and the board of directors is 6.2 years and 7 years respectively.

Key information

Krish Krishnan

Chief executive officer

US$15.6m

Total compensation

CEO salary percentage5.14%
CEO tenure10.2yrs
CEO ownership5.4%
Management average tenure6.2yrs
Board average tenure7yrs

Recent management updates

Recent updates

The Rare Disease Rocket Ship

Krystal Biotech reports tomorrow, February 17, 2026. The narrative is no longer about survival; it’s about dominance.

Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update

Feb 10

Investors Shouldn't Be Too Comfortable With Krystal Biotech's (NASDAQ:KRYS) Earnings

Nov 10
Investors Shouldn't Be Too Comfortable With Krystal Biotech's (NASDAQ:KRYS) Earnings

Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher

Oct 09
Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher

Why We're Not Concerned Yet About Krystal Biotech, Inc.'s (NASDAQ:KRYS) 26% Share Price Plunge

May 23
Why We're Not Concerned Yet About Krystal Biotech, Inc.'s (NASDAQ:KRYS) 26% Share Price Plunge

Should You Be Adding Krystal Biotech (NASDAQ:KRYS) To Your Watchlist Today?

Apr 21
Should You Be Adding Krystal Biotech (NASDAQ:KRYS) To Your Watchlist Today?

Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus

Feb 21

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

Oct 14
User avatar

Expanding Global Reach With VYJUVEK Set To Skyrocket Revenue And Sharpen Market Edge

International expansion and upcoming product launches indicate significant potential for revenue growth and market diversification.

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

Jul 31

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

Feb 28

Krystal Biotech: Ready For Launch

Feb 20

CEO Compensation Analysis

How has Krish Krishnan's remuneration changed compared to Krystal Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

US$205m

Sep 30 2025n/an/a

US$199m

Jun 30 2025n/an/a

US$147m

Mar 31 2025n/an/a

US$124m

Dec 31 2024US$16mUS$802k

US$89m

Sep 30 2024n/an/a

US$52m

Jun 30 2024n/an/a

US$106m

Mar 31 2024n/an/a

US$57m

Dec 31 2023US$6mUS$733k

US$11m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$135m

Dec 31 2022US$3mUS$645k

-US$140m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$115m

Mar 31 2022n/an/a

-US$104m

Dec 31 2021US$7mUS$581k

-US$70m

Sep 30 2021n/an/a

-US$58m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$764kUS$498k

-US$32m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$631kUS$366k

-US$19m

Compensation vs Market: Krish's total compensation ($USD15.60M) is above average for companies of similar size in the US market ($USD7.93M).

Compensation vs Earnings: Krish's compensation has increased by more than 20% in the past year.

CEO

Krish Krishnan (60 yo)

10.2yrs
Tenure
US$15,603,652
Compensation

Mr. Krish S. Krishnan, M.S., M.B.A., is Founder of Krystal Biotech, Inc. since 2016. He has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since 2016. Mr. Krishnan is Co-Owne...

Leadership Team

NamePositionTenureCompensationOwnership
Krish Krishnan
Founder10.2yrsUS$15.60m5.36%
$ 399.9m
Suma Krishnan
Founder10.2yrsUS$8.24m5.14%
$ 383.4m
Kathryn Romano
Executive VP & Chief Accounting Officer6.2yrsUS$3.05m0.077%
$ 5.7m
John Thomas
EVP, General Counsel & Corporate Secretaryno datano data0.0022%
$ 164.0k
John Karakkal
Vice President of North American Sales & Marketingno datano datano data
Stephane Paquette
Senior Vice President of Corporate Developmentno datano datano data
Josh Suskin
Senior Director & Head of US Human Resourcesno datano datano data
Laurent Goux
EVP & GM of Europeno datano data0.0031%
$ 234.1k
David Chien
Senior Vice President of Clinical Development4.2yrsno datano data
Christine Wilson
Senior VP & Head of US Commercialless than a yearno datano data
Trevor Parry
Senior Vice President of Product Developmentno datano datano data
David Sweet
Director of Clinical Developmentno datano datano data
6.2yrs
Average Tenure
60yo
Average Age

Experienced Management: KRYS's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Krish Krishnan
Founder10.2yrsUS$15.60m5.36%
$ 399.9m
Suma Krishnan
Founder10.2yrsUS$8.24m5.14%
$ 383.4m
Daniel Janney
Lead Independent Director9.3yrsUS$702.69k0%
$ 0
Dino Rossi
Independent Director8.8yrsUS$670.19k0.27%
$ 20.1m
Julian Gangolli
Independent Director7yrsUS$670.19k0%
$ 0
E. Sutherland
Independent Director4.2yrsUS$655.19k0%
$ 0
Christopher Mason
Independent Director5.2yrsUS$648.19k0%
$ 0
Catherine Mazzacco
Independent Director3yrsUS$650.19k0%
$ 0
Samuel Broder
Chairman of Scientific Advisory Board6.2yrsno datano data
7.0yrs
Average Tenure
60yo
Average Age

Experienced Board: KRYS's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/12 04:26
End of Day Share Price 2026/03/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Krystal Biotech, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caroline PalomequeBerenberg
Alec StranahanBofA Global Research
Justin ZelinB. Riley Securities, Inc.